HBV Core Promoter Inhibition by Tubulin Polymerization Inhibitor (SRI-32007)
Approximately 257 million people chronically infected with hepatitis B virus (HBV) worldwide are at risk of developing hepatocellular carcinoma (HCC). However, despite the availability of potent nucleoside/tide inhibitors, currently there are no curative therapies for chronic HBV infections. To iden...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Advances in Virology |
| Online Access: | http://dx.doi.org/10.1155/2020/8844061 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|